• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Generic version of OAB drug now available

Article

A generic version of the overactive bladder drug trospium chloride has received FDA approval and is now available.

A generic version of the overactive bladder drug trospium chloride has received FDA approval and is now available.

Perrigo Co. said it had previously prevailed in litigation related to the drug’s launch at both the district and appellate levels. The product has begun shipping immediately, according to the company.

Trospium, also marketed under the brand name Sanctura XR, is a once-daily medication for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Related Content

PTNS therapy for OAB found durable at 3 years

 

Newer overactive bladder agent viable alternative to antimuscarinics

Related Videos
Mature woman with her doctor | Image Credit: © pucko_ns - stock.adobe.com
Female patient talking with female doctor | Image Credit: © rocketclips - stock.adobe.com
David Gilbert answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Megan S. Bradley, MD, answers a question during a Zoom video interview
African American patient explaining issues to Asian doctor using tablet | Image Credit: © rocketclips - stockadobe.com
Woman talking with doctor | Image Credit: © bongkarn - stock.adobe.com
Caroline Dowling, MBBS, MS, FRACS (Urol), answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.